Discovery Labs Announces Second Quarter Conference Call and Webcast

Warrington, Pennsylvania, UNITED STATES


WARRINGTON, Pa., July 30, 2008 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today it will be hosting a conference call on Wednesday, August 6, 2008 at 10:00 a.m. EDT. Management will discuss financial results for the second quarter of 2008 and provide an overall business update.

Participants are encouraged to access this audio webcast through a live broadcast on the Company's website at www.discoverylabs.com. The webcast is also accessible on the Internet http://investor.shareholder.com/media/eventdetail.cfm?mediaid=32757&c=DSCO&mediakey=448BA3166CAB48F31414C3F51085C437&e=0. It is recommended that participants log onto one of these sites at least 15 minutes prior to the call. The Internet broadcast will be available for up to 30 days after the call at both website addresses.

The call in number is 866-332-5218. The international call in number is 706-679-3237. The replay number to hear the conference call is 800-642-1687 or 706-645-9291. The passcode is 58449535.

About Discovery Labs

Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Replacement Therapies (SRT) for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' technology produces a peptide-containing synthetic surfactant that is structurally similar to pulmonary surfactant. Discovery Labs believes that, with its proprietary technology, SRT has the potential, for the first time, to advance respiratory medicine and address a variety of respiratory diseases affecting neonatal, pediatric and adult patients.

SURFAXIN(r), the Company's lead product from its SRT pipeline, is the subject of an Approvable Letter from the FDA for the prevention of Respiratory Distress Syndrome in premature infants. SURFAXIN is also being developed for other neonatal and pediatric indications. AEROSURF(tm), Discovery Labs' aerosolized SRT, is being developed to potentially obviate the need for intubation and conventional mechanical ventilation and holds the promise to significantly expand the use of surfactants in respiratory medicine. For more information, please visit our website at www.Discoverylabs.com.


                    

        

Contact Data